Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea
- PMID: 12354851
- PMCID: PMC130863
- DOI: 10.1128/JCM.40.10.3596-3601.2002
Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea
Abstract
Neisseria gonorrhoeae infection remains relatively common in the United States, representing a public health challenge. Ligase chain reaction (LCR) is both highly sensitive and specific for the detection of N. gonorrhoeae in urine and patient-obtained vaginal swab specimens. Because of the LCR test's exquisite sensitivity, it may potentially detect DNA from nonviable organisms following effective therapy, leading to false-positive test results and unnecessary additional treatment. The purpose of the present study was to determine the duration that gonococcal DNA is detectable by LCR following therapy for uncomplicated gonococcal infection. One hundred thirty men and women between the ages of 16 and 50 years presenting to a sexually transmitted disease clinic with urogenital gonorrhea were enrolled. After the standard history was taken and a genital examination was done, the patients were asked to submit either a urine specimen (men) or a urine specimen plus a self-obtained vaginal swab specimen (women) for N. gonorrhoeae testing by LCR at the initial visit and each day during the study period. At enrollment, patients were treated with single doses of ofloxacin, cefixime, or ceftriaxone. The median time to a negative urine LCR test result was 1 day for the men (mean, 1.6 +/- 0.14 days) and 2 days for the women (mean, 1.7 +/- 0.19 days). Among the women the clearance time was significantly longer for vaginal specimens (mean, 2.8 +/- 0.30 days) than for urine specimens (mean, 1.7 +/- 0.11 days). Irrespective of patient gender and specimen type, gonococcal DNA can be expected to be absent from urogenital specimens within 2 weeks following successful therapy.
Figures
References
-
- Bianchi, A., M. Bogard, G. Cessot, J. M. Bohbot, J. E. Malkin, and J. M. Alonso. 1998. Kinetics of Chlamydia trachomatis clearance in patients with azithromycin, as assessed by first void urine testing by PCR and transcription-mediated amplification. Sex. Transm. Dis. 25:366-367. - PubMed
-
- Centers for Disease Control and Prevention. 2001. Sexually transmitted disease surveillance 2000. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Ga.
-
- Centers for Diseases Control and Prevention. 1998. 1998 guidelines for the treatment of sexually transmitted diseases. Morb. Mortal. Wkly. Rep. 47:1-116. - PubMed
-
- Gaydos, C. A., K. A. Crotchfelt, M. R. Howell, S. Kralian, P. Hauptman, and T. C. Quinn. 1998. Molecular amplification assays to detect chlamydial infections in urine specimens from high school female students and to monitor the persistence of chlamydial DNA after therapy. J. Infect. Dis. 177:417-424. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
